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Objective: Missing data can produce biased estimates in interrupted time series (ITS) 
analyses. We reviewed recent ITS investigations on health topics for determining 1) the 
data management strategies and statistical analysis performed, 2) how often missing data 
were considered and, if so, how they were evaluated, reported and handled.
Study Design and Setting: This was a scoping review following standard recommendations 
from the PRISMA Extension for Scoping Reviews. We included a random sample of all ITS 
studies that assessed any intervention relevant to health care (eg, policies or programmes) with 
individual-level data, published in 2019, with abstracts indexed on MEDLINE.
Results: From 732 studies identified, we finally reviewed 60. Reporting of missing data was 
rare. Data aggregation, statistical tools for modelling population-level data and complete case 
analyses were preferred, but these can lead to bias when data are missing at random. 
Seasonality and other time-dependent confounders were rarely accounted for and, when 
they were, missing data implications were typically ignored. Very few studies reflected on 
the consequences of missing data.
Conclusion: Handling and reporting of missing data in recent ITS studies performed for 
health research have many shortcomings compared with best practice.
Keywords: interrupted time series analysis, segmented regression, missing data, multiple 
imputation, scoping review
Introduction
Interrupted time series (ITS) is a widely used quasi-experimental approach that 
evaluates the potential impact of an intervention over time, using longitudinal data.1 
ITS has become more widespread in health research in the past decade.2,3 The use 
of observational patient-level data is frequent in ITS,3–6 but routinely collected 
health data usually bring missing data issues.7 Hudson et al3 detected that only 5% 
of the ITS studies in health care reported how missing data were handled. Current 
recommendations in the ITS literature1 focus the attention on autocorrelation, 
seasonality and sample size as potential sources of bias, whereas little advice is 
given on reporting and handling of missing data.
Missing data management and statistical analysis can be crucial for any ITS 
study. In a preliminary search,3–6 we identified two practices among researchers 
that could affect the validity of ITS estimates. First, before any statistical 
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analysis, they opt to aggregate individual-level data into 
population-level data. For example, they average all the 
available outcome values at each predefined time-point 
(eg, month) and use these averages as population-level 
outcome values in the subsequent time series analyses. 
We call this the “averaging step” and, as we will explain 
later, this can lead to bias in the “aggregate-level” data 
analysis. Second, researchers are using statistical tools/ 
approaches for modelling these aggregate-level data (eg, 
autoregressive integrated moving average [ARIMA]) that 
have not been designed to account for missing data at the 
individual level.
ITS guidelines recommend controlling for potential 
confounders, such as autocorrelation or seasonality, using 
tools designed for population-level analyses and ignoring 
the missing data problem at the individual level.1,8–10 
Autocorrelation, whereby two consecutive data points 
can be more correlated with each other, could appear 
smaller than if the exact same individuals were included 
over time. If outcome data from same individuals are 
missing and not replaced with data from exchangeable 
individuals, the undervalued autocorrelation can induce 
bias in the ITS estimates. Seasonality, which is defined 
by cyclic patterns on the outcome over time at population 
level, can also be distorted by unseasonal missing data 
patterns at individual level. Thus, traditional approaches 
to control for seasonality could be insufficient as well.
Five systematic reviews exploring methodological 
characteristics of health research with ITS designs have 
previously been reported.2,3,11–13 They have contributed 
towards detecting gaps in reporting and the use of standard 
ITS analyses. However, these studies did not focus on the 
particular problem of applying these standards to the ana-
lysis of individual-level records with missing values. In 
particular, the missing data issues related to the 
averaging step and the selected statistical approach have 
been ignored by previous methodological or review stu-
dies of ITS.
Therefore, this review focuses on the practices in miss-
ing data handling and analysis that are prevalent in the ITS 
literature; particularly, how researchers are addressing the 
problem of having missing data at the individual level.
The present study aims to describe current practices in 
missing data handling for ITS studies performed in health 
research. In particular, we were interested in those studies 
that had access to individual-level data. With this aim, we 
reviewed ITS investigations on health topics to 1) deter-
mine the data management strategies and statistical 
analyses performed in these studies, and 2) determine 
how often missing data were considered and, if so, how 
they were evaluated, reported and handled in the analysis.
Methods
We conducted this study following the steps previously 
specified in a scoping review protocol (https://doi.org/10. 
5522/04/14327717.v1), and following the standard recom-
mendations from the PRISMA Extension for Scoping 
Reviews.14 “Scoping reviews” are alternatives to systema-
tic reviews, which are especially suitable for investigating 
more general questions such as common practices in 
research.15 For that reason, scoping reviews usually omit 
any critical appraisal within the reviewed articles, do not 
assess the risk of bias across the studies and do not end 
with meta-analyses.
Inclusion and Exclusion Criteria
We included studies of ITS that assessed any intervention 
relevant to health care (eg, policies or programmes), with 
no restrictions on participants, the language of publication 
or the type of outcome. Both ITS and controlled ITS 
studies were included. We excluded systematic reviews, 
meta-analyses, randomised controlled trials, protocols, 
grey literature (eg, government reports), editorials, letters 
to editors, retraction papers, methodological studies, stu-
dies with no access to individual-level data and studies 
that used Google Trends data only. Studies whose full text 
was not available – after trying several avenues – were 
also excluded. Studies with fewer than two time-points 
before and two after the first interruption time-point in 
the ITS were excluded. The access to individual-level 
data was verified in the methods section of each article, 
usually in the subsection describing the settings, sample or 
population studied (eg, if they reported data routinely 
collected from patients).
Search Strategy
We used the MEDLINE® and Epub Ahead of Print, In- 
Process & Other Non-Indexed Citations and Daily data-
base (Ovid version) on 08 February 2020, to identify ITS 
studies published from 01 January 2019 to 
31 December 2019. The search strategy, given in 
Appendix A, was prepared by the co-authors, and 
reviewed by an information specialist from the UCL 
Library.
JCB performed the automatic search with the Ovid 
tool, removed duplications using EndNote, and screened 
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titles and abstracts manually by the search for inclusion. 
An independent reviewer (Frank Peralta [FP] orcid.org/ 
0000-0001-5964-6971) double-assessed 10% of same 
titles and abstracts and, if they agreed, they would proceed 
to screen using a full-text version of the publications. FP 
also assessed 10% of the full texts and, in the absence of 
disagreement, JCB would proceed to randomly select 60 
publications for final data extraction, using a random num-
ber generator with Stata.16 We prespecified a sample size 
of 60 as enough to obtain information on practices in ITS 
studies. This decision was based on key questions invol-
ving binary answers which could be summarised as pro-
portions. We set our sample size with the following 
reasoning. The largest standard error (SE) for 
a proportion with n=60 is for proportion 0.5, which has 
SE 0.06. For example, estimating that 50% of the studies 
had adequately handled individual-level missing data 
would come with 95% CI (37%, 63%). A third colleague 
was available to help in any disagreement at any stage of 
this process, whenever it was needed.
Data Extraction and Analysis
The data extraction form (Appendix B) was reviewed and 
validated by the co-authors and the information specialist 
from the UCL Library. From the 60 selected publications, 
six full-text original articles were randomly selected and 
were reviewed by FP and JCB independently. If there were 
no disagreements, JCB would proceed to review the other 
54 articles.
Data extracted from the articles can be categorised into 
three topics: general characteristics, data management and 
statistical analysis, and missing data reporting and handling.
General Characteristics of the ITS Studies
First author, journal, country, study design (eg, ITS, con-
trolled ITS), participants, type of intervention, level of 
intervention (eg, country, hospital), most granulated clus-
ter available (eg, hospital, individual-level) and longitudi-
nal follow-up (eg, prospective cohort or panel).
Data Management and Statistical Analysis
Data source, linked data, outcome type (eg, continuous, 
proportion), number of time-points, time-point unit, aver-
aging step (yes/no), statistical model (eg, ARIMA, mixed- 
effects model), confounder reported (yes/no) and confounder 
adjusted for (yes/no), autocorrelation (considered, tested 
with, concluded by test, controlled by), seasonality (consid-
ered, tested with, concluded by test, controlled by), time- 
dependent variable (considered, handled by) and other meth-
odological issues (considered, handled by). The averaging 
step is the step from which the outcome analysed at the 
population level is the average of more granulated outcome 
data (eg, individual-level data) at each time point defined for 
the ITS (eg, one average outcome for each week).
Missing Data Reporting and Handling
Missing data considered (yes/no), proportion reported, the 
missing data mechanism (considered, reported), the 
method for handling missing data (considered, reported) 
and sensitivity analysis (considered, reported).
We based this data extraction on the primary outcome, 
or the first outcome mentioned if the authors did not set 
a primary outcome.
We summarised data using descriptive statistics (num-
bers and percentages or median, interquartile range (IQR), 
minimum and maximum values). Some cross-tabulations 
of frequencies were used when needed, and these are 
reported as supplemental material.
Results
The search strategy identified 732 titles and abstracts from 
MEDLINE Ovid (Figure 1). After removing two duplicates, 
we excluded 209 titles and abstracts that did not meet the 
inclusion criteria, leaving 521 full-text studies to be checked 
for eligibility. From this full-text selection, we excluded 180, 
most of them having only population-level data (n=104). After 
exclusion, 341 articles were suitable for the final screening; 
thus, we randomly selected 60 of them, and the list of these 
studies is provided in Appendix C. Since there were no dis-
agreements during the screening and data extraction process, 
FP and JCB only double-assessed 10% of the full-text copies.
Most of the 60 studies were from the USA (n=28, 47%), 
the UK (n=7, 12%) or Canada (n=4, 7%) (Table 1). Only two 
studies (3%) were not labelled as ITS studies, although they 
used a single-ITS design (their authors described thems as 
segmented regression analyses). In total, 48 (80%) studies 
used a single-ITS design (ie, no control group), whereas 10 
(17%) applied a more sophisticated controlled-ITS design.17 
Patients were the most prevalent participants (n=38, 63%), 
followed by health personnel (n=6, 10%) or the general 
population (n=4, 7%). Policies (n=16, 27%), 
programmes (n=14, 23%) and focused interventions (n=15, 
25%) were the most common interventions evaluated. These 
interventions were frequently applied at a hospital (n=18, 
30%) or country level (n=17, 28%). Although all of these 
studies (n=60, 100%) had access to individual-level data, 
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owing to the nature of the studied ITS outcome (eg, the 
number of new patients before and after the intervention), 
only 32 (53%) could have followed/analysed the ITS 
outcome at an individuallevel (ie, repeated measures of the 
ITS outcome within individuals). However, other coarser 
clusters could have been followed over time, for example, 
Figure 1 PRISMA diagram for the scoping review. 
Notes: PRISMA figure adapted from Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate 
health care interventions: explanation and elaboration. Journal of Clinical Epidemiology. 2009;62(10)e1-e34. Creative Commons.28
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hospitals (n=13, 22%), hospital units (n=3, 5%), health facil-
ities (n=3, 5%) or general practices (GPs) (n=3, 5%) (ie, ITS 
with multiple groups). A cross-table between level of inter-
vention and more granulated clusters available is given in 
Appendix D. This provides an approximation of how often 
a researcher could move from modelling population ITS 
trajectories with population-level data points (ie, only one 
ITS outcome average at each time-point) to modelling the 
trajectories with finer level data, which were also available 
(eg, individual- or hospital-level data for being modelled 
with mixed-effects or generalised estimating equation 
[GEE] models). The longitudinal follow-up of the data col-
lected for all of these ITS studies were mostly retrospective 
and were available at individual level (n=25, 42%) or other 
less granulated cluster levels (n=21, 35%).
In most studies, data were routinely collected (n=46, 77%), 
which is often a source of missing data, since the data collec-
tion procedures were not designed for an ITS study or even for 
any research (eg, ITS outcomes were not collected at similar 
intervals across patients, such as weight measurement may 
have been taken at different times) (Table 2). Data were not 
usually linked to external data (n=10, 17%). The most common 
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General population 4 (6.7)
Health personnel 6 (10)
Health personnel and patients 6 (10)




Guideline/protocol/sound publication or evidence 9 (15)
Focused intervention 15 (25)
Policy 16 (26.7)
Programme 14 (23.3)
Relevant or historical event 3 (5)
Treatment 3 (5)
Level of Intervention




Hospitals, group of 8 (13.3)
(Continued)
Table 1 (Continued). 
n (%)
Individual level 2 (3.3)
State/province/county 10 (16.7)
Fire departments 1 (1.7)
Most Granulated Cluster Available
GP 3 (5)
District 2 (3.3)
Fire department 1 (1.7)
Group of patients (by diagnosis) 1 (1.7)
Health facility 3 (5)
Hospital 13 (21.7)
Hospital unit 3 (5)
Household 1 (1.7)
Individual level 32 (53.3)
Medications 1 (1.7)
Longitudinal Follow-up
Prospective cohort (individuals) 8 (13.3)
Prospective panel (cluster) 6 (10)
Retrospective cohort (individuals) 25 (41.7)
Retrospective panel (cluster) 21 (35)
Abbreviations: CITS, controlled interrupted time series; ITS, interrupted time 
series; SR, segmented regression; GP, general practice.
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ITS outcome type was a proportion (n=39, 65%) and the most 
common unit of the follow-up time was a month (n=36, 60%). 
The median number of time-points used in the ITS analysis 
was 38 (IQR=55). The averaging step was performed in 47 
(78%) of the studies. One example of this is illustrated by Close 
et al.18 They averaged the number of stroke admissions per 
practice per month (73 practices observed from 2011 to 2018), 
for modelling the ITS on the aggregated data (ie, one average 
point at each month). They then used an ordinary least 
squares model with Newey–West standard errors for the ITS 
analysis. The most typical statistical model was segmented 
regression (SR) with ordinary least squares estimators (SR- 
OLS, n=23, 38%) or with maximum likelihood type estimators 
(SR with generalised linear models [SR-GLM], n=15, 25%). 
A cross-table between averaging step and statistical model is 
available in Appendix E, showing how researchers combine 
them in standard ITS studies. Confounding was considered in 
41 (68%) of the studies, but adjustment for confounding was 
only done in 33 studies (55%).
Many researchers considered the autocorrelation problem 
(n=41/60, 68%) (Table 3). However, descriptions about how 
they tested and handled autocorrelation were sporadic. For 
example, one-third did not report the test they applied – if 
any – to evaluate autocorrelation (n=13/41, 32%). This was 
different for those who worked with individual-level data and 
fitted GEE or mixed-effects models, reporting within- 
individual correlation by design (n=11/41, 27%), since they 
did not usually address the autocorrelation problem at the 
population level. Among those who identified autocorrela-
tion issues in their data (n=36/41, 88%), the use of Newey– 
West standard errors (n=7/36, 19%) or autoregressive error 
terms (n=8/36, 22%) was preferred.
The seasonality issue was considered in about one- 
third of the studies (n=19/60, 32%) and, in most cases, 
it was not formally tested (n=14/19, 74%). In studies 
with observation periods >1 year (n=52/60, 87%), sea-
sonality was considered in 17/52 (33%). Regardless of 
the use of a formal test – graphical inspection may have 
been used, but not described – 18/19 (95%) concluded 
that there were seasonality effects and made an attempt 
to control for them. The most popular way to control for 
seasonality (n=12/18, 67%) was to include covariates of 
time (eg, dummy variables of months) in the ITS 
models.
Table 2 Data and Statistical Analyses of the Included Interrupted 
Time Series Studies (N=60)
n (%)
Data Source
Collected for the study (prospective) 14 (23.3)































Mixed effects (random intercept only) 4 (6.7)







Abbreviations: IQR, interquartile range; ARIMA, autoregressive integrated mov-
ing average; SR, segmented regression; GEE, generalised estimating equation; GLS, 
generalised least squares; OLS, ordinary least squares.
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Most studies (n=49/60, 82%) considered that time- 
dependent confounding could not be handled by a single 
ITS design.17 However, more than two-thirds of the studies 
only reported the problem as a limitation (n=34/49, 70%), 
whereas less than one-quarter (n=10/49, 20%) used a control 
group to address the limitation. Other methodological issues 
related to the ITS design were also considered (n=25/60, 
42%), using sensitivity analyses to evaluate the impact of 
these issues on the results (n=6/25, 24%). For example, 
sensitivity analyses were used by extracting groups of 
patients in order to understand whether unmeasured events – 
potentially experienced by some groups – could affect the 
ITS outcome trajectories (n=3/25, 12%). Likewise, sensitiv-
ity analyses were applied to contrast the preselected ITS 
impact model1,19 with other feasible models (n=3/25, 12%).
Only 13/60 studies (22%) reported issues related to 
missing data, with considerable variation across the pro-
portion of missing values reported. Although many studies 
worked on retrospectively collected data (n=46/60, 77%) 
(Table 2), with irregular recording expected for any 
Table 3 Reporting and Handling of Methodological Issues in the 
Included Interrupted Time Series Studies (N=60)
n (%)
Autocorrelation – Considered (n=60)
No 19 (31.7)
Yes 41 (68.3)




Within-individual correlation by design 11 (26.8)
Autocorrelation function 3 (7.3)
Autocorrelation probability 2 (4.9)
Not specified 13 (31.7)
Residuals examination 1 (2.4)
Autocorrelation – Concluded by Test (n=41)
No 5 (12.2)
Yes 36 (87.8)
Autocorrelation – Controlled By (n=36)
Cochrane–Orcutt 1 (2.8)
GEE models 6 (16.7)
Newey–West standard errors 7 (19.4)
Prais–Winsten 2 (5.6)
Autoregressive error term 8 (22.2)
Mixed models 5 (13.9)
Not specified 7 (19.4)
Seasonality – Considered (n=60)
No 41 (68.3)
Yes 19 (31.7)
Seasonality – Tested With (n=19)
Dickey–Fuller 1 (5.3)
Autocorrelation/partial autocorrelation function 2 (10.5)
No formal test 14 (73.7)
Not possible (short period) 1 (5.3)
Regression diagnosis test 1 (5.3)
Seasonality – Concluded by Test (n=19)
No 1 (5.3)
Yes 18 (94.7)
Seasonality – Controlled By (n=18)
ARIMA parameter 1 (5.6)
Covariate in the model 12 (66.7)
Decomposition 1 (5.6)
Not handled (reported as limitation) 2 (11.1)
Seasonal ARIMA 2 (11.1)




Table 3 (Continued). 
n (%)
Time-Dependent Variable – Handled By (n=49)
Control group 10 (20.4)
Control outcome 1 (2)
Covariate (exploration) 1 (2)
Covariate in the model 3 (6.1)
Reported as a limitation, not handled 34 (69.4)
Other Issues – Considered (n=60)
No 35 (58.3)
Yes 25 (41.7)
Other Issues – Handled By (n=25)
Bonferroni adjustment (p values) 1 (4)
Adjusted for survey design 1 (4)
Aggregate ecological design (reported as a limitation) 1 (4)
Confounders not controlled (reported as a limitation) 1 (4)
Minimising immortal time bias 1 (4)
Non-stationary (ARIMA controlled) 2 (8)
Overdispersion evaluation (Poisson models) 2 (8)
Secular trends (reported as a limitation) 2 (8)
Sensitivity analysis (extracting patients) 3 (12)
Sensitivity analysis (impact model) 3 (12)
Sensitivity analysis (various) 6 (24)
Subgroup analysis 2 (8)
Abbreviations: GEE, generalised estimating equation; ARIMA, autoregressive 
integrated moving average.
Clinical Epidemiology 2021:13                                                                                                      https://doi.org/10.2147/CLEP.S314020                                                                                                                                                                                                                       
DovePress                                                                                                                         
609
Dovepress                                                                                                                                                   Bazo-Alvarez et al
Powered by TCPDF (www.tcpdf.org)
outcome at the individual level (n=32/60, 53%) (Table 1), 
only one study (n=1/13, 8%) explicitly reported this as an 
issue (missing data on the ITS outcome <60%) (Table 4). 
Only two studies (n=2/13, 15%) considered the missing 
data mechanisms and their implications on the analysis, 
reporting missing at random (MAR) and missing not at 
random (MNAR) as potential mechanisms behind their 
missing values (Table 4). The 13 studies reported the 
method used for handling missing data, complete case 
analysis (CCA) being the most popular (n=11/13, 85%). 
Interestingly, in 2/6 investigations using mixed-effects 
models (Table 2), the researchers recognised how these 
models can help to handle missing data on the ITS out-
come. Missing data were evaluated with sensitivity ana-
lyses in two studies only (n=2/13, 15%) (Table 4). In one, 
results from multiple imputation and CCA were compared. 
In the other, they compared results from using a missing 
data indicator – a separate “missing data” – against results 
from CCA.
Discussion
We identified at least five methodological issues directly asso-
ciated with missing data handling in ITS studies. First, many 
studies have been using the averaging step of summarising the 
ITS outcome at each time-point, even if they had the opportu-
nity to directly model the outcome with longitudinal indivi-
dual-level data (or at least with data more granulated than the 
population level in order to avoid data aggregation). Second, 
analyses of population-level data (eg, aggregate-level SR) 
were more commonly used than analysis of individual-level 
data (eg, mixed-effects models). Third, missing data on cov-
ariates at baseline are commonly handled by CCA, losing 
valuable information and potentially leading to bias if ITS 
estimates are adjusted for these covariates. Fourth, seasonality 
and other time-dependent confounders are rarely controlled 
and, when they are, missing data implications are typically 
ignored. Finally, reporting of missing data was omitted by most 
ITS studies. Further reflections on the potential consequences 
of missing data, and the subsequent selection of best methods 
to handle missing values, are rarely covered in ITS studies.
The averaging step forces the data missing at the indi-
vidual level to artificially disappear at the population level, 
generating the false impression of an issue being con-
trolled. For example, if the outcome data are missing at 
random conditional on a fully observed covariate at the 
individual level, and we calculate a simple average across 
individuals at each time-point, the covariate that explains 
the outcome missingness will become unobserved at the 
aggregate level (ie, missing not at random; see Appendix 
F).20 This is a potential source of bias that none of the 
studies reviewed has mentioned as a limitation. The data 
used in ITS studies are often based on routinely collected 
data and many such data sources have a large amount of 
missing outcome data often measured at irregular time 
Table 4 Reporting and Handling of Missing Data Issues in the 
Included Interrupted Time Series Studies (N=60)
n (%)
Missing Data – Considered (n=60)
No 47 (78.3)
Yes 13 (21.7)
Missing Data – % Reported (n=13)
% Not reported, but declared as an issue to be solved 2 (15.4)
Covariates <30%/outcome <50% 1 (7.7)
Covariates at baseline (<1% each, not combined) 1 (7.7)
Covariates at baseline (<10% each, not combined) 2 (15.4)
Covariates at baseline (<2%, flow chart) 1 (7.7)
Covariates at baseline (<25% each, not combined) 1 (7.7)
Covariates at baseline (<25%, flowchart) 1 (7.7)
Covariates at baseline (<30% each, not combined) 1 (7.7)
Covariates at baseline (<5%, flowchart) 1 (7.7)
Outcome <60% 1 (7.7)
Smoking (one case), outcome irregularly recorded 1 (7.7)
Missing Data Mechanism – Considered (n=13)
No 11 (84.6)
Yes 2 (15.4)
Missing Data Mechanism – Reported (n=2)
MAR 1 (50)
MNAR 1 (50)
Method for Handling Missing Data – Considered (n=13)
No 0 (0)
Yes 13 (100)
Method for Handling Missing Data – Reported (n=13)
CCA 11 (84.6)
Mixed intercept model for handling missing outcomes 1 (7.7)
Mixed intercept and slope model for handling missing 
outcomes
1 (7.7)




Sensitivity Analysis for Missing Data Mechanism – 
Reported (n=2)
Comparing results from MICE versus CCA 1 (50)
Comparing results from using a “missing data category” 
versus CCA
1 (50)
Abbreviations: MAR, missing at random; MNAR, missing not at random; CCA, 
complete case analysis; MICE, multiple imputation by chained equations.
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intervals. This is particularly important for ITS designs, 
for which it is expected to have the outcome regularly 
measured at each time-point.21 With many outcome gaps 
due to irregular recording, researchers frequently selected 
convenient time periods as units of time (eg, months) and 
averaged all the available records to set a unique outcome 
value for each time-point/unit. Many may not be aware 
that such an approach leads to potential bias owing to data 
becoming missing not at random, as explained above.
The frequent use of the averaging step seems to be related 
to the standard use of fixed-effect models, which is abundant in 
the ITS literature and guidelines.1,3 Traditionally, ITS 
analyses have been performed on population-level data and, 
more recently, on data aggregated to this level.12 Researchers 
would have seen the averaging step as an intuitive way to adapt 
the individual-level data into the population-level data that 
guidelines teach them to model.1 With no methodological 
studies on the consequences of the averaging step or recom-
mendations from the ITS guidelines on how to handle missing 
data,2 researchers do not have knowledge of the existence of 
the issue such that they would be motivated to improve 
practice.
Most researchers handle missing data on confounders at 
baseline by using CCA, taking similar actions when model-
ling interaction terms in controlled ITS studies, but again 
without major reflection on the implications. For example, if 
the CCA omitted an observation, the final ITS estimator 
could reduce precision or be biased.20 We have confirmed 
that the most common approach for handling missing data in 
the reviewed studies was CCA. Only one study reported the 
use of multiple imputation and used the standard chained 
equation method (MICE).22 This method may bring conge-
niality problems when applied to multilevel data (eg, indivi-
dual follow-up, and adjusting for a dummy month variable at 
an aggregate level to control for seasonality).23 Specification 
of a congenial imputation model is more complex for MICE 
when researchers need to introduce time-varying confoun-
ders or interaction terms in the models, both of which are 
expected steps in many controlled ITS studies.17 For these 
more complex scenarios, multilevel multiple imputation 
methods are preferred24 owing to their flexibility to enable 
interaction terms and confounders to be introduced at differ-
ent levels.
Seasonality and other time-dependent confounders are 
barely controlled in ITS studies and, when they are, missing 
data implications are typically ignored. Following an aver-
aging-step procedure, the missing data at the individual level 
can affect the way the seasonality is observed at the aggregate 
level; for example, if the outcome is MAR on sex, while the 
missingness proportion follows a seasonal pattern for men and 
data are fully observed for women (see Appendix G). Since the 
preferred method to control for seasonality seems to be to 
include a dummy variable of time in the models (eg, month), 
the control will still incorporate noise from the points describ-
ing the seasonality at the aggregate level. Using mixed effects 
to model the ITS with individual-level data, the seasonality 
could be controlled by specifying the structure of residual 
errors (ie, when the intervention is applied at the population 
level). Under the MAR assumption, these mixed-effect models 
are unbiased.25 However, this or similar control alternatives 
were not reported by any of the studies included in this review.
There is a lack of missing data reporting in ITS studies, 
and further reflections on the potential consequences of miss-
ing data mechanisms and on the best methods to handle 
missing values are needed. Previous reviews have found an 
even lower proportion of missing data reporting,3 which 
indicates that this gap is in the ITS literature. Only one 
study among all those reviewed reflected on how 
a potential MNAR mechanism might affect its results.26 
However, no sensitivity analysis was performed, by any 
study, to consider the impact that a possible MNAR mechan-
ism could have on the final estimates.27 Considering that 
most of the ITS studies are based on routinely collected 
data, the control that researchers can have over missing 
data is minimal; thus, a thorough evaluation/reflection on 
the missingness mechanisms is the only action that is viable 
in practice. After such an evaluation, the selection of the best 
method to handle missing values can be best informed, lead-
ing to better alternatives than CCA, which is seldom sup-
ported by a rationale in the ITS studies.
In general, the findings of this study are consistent with 
those reported by previous reviews. From 16 ITS studies 
published between 1976 and 2011, Polus et al11 found five 
with no statistical models and zero studies using mixed- 
effect models. Our review focused on 60 publications 
dated 2019, finding only six studies using mixed-effects 
models. This combined evidence tells us that researchers’ 
preferences have not changed dramatically during the past 
decade. Jandoc et al,2 who reviewed ITS studies in drug 
utilisation published between 1984 and 2013, found that 
>92% of data sources were administrative data (routinely 
collected). As they reported a similar proportion of routi-
nely collected data as in this review, we externally con-
firmed that the missing data prevalence for ITS is still 
a problem. Hudson et al3 reported that continuous ITS 
outcomes were more frequent, whereas we found that 
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proportion was the most common. Differences seem to 
come from the way in which Hudson et al would have 
classified the outcomes. For them, the outcome type would 
have been defined by the model used (eg, if researchers 
fitted an OLS model, then the outcome should be typified 
as continuous). More recently, Turner et al12 identified that 
individual-level outcomes of one type (eg, binary) are 
often aggregated in population-level outcomes of another 
type (eg, proportion, counts, rates and continuous), under-
using individual-level analysis options (eg, mixed-effects 
models). Ewusie et al13 identified data aggregation in more 
than one level; for example, average of patients’ data at 
the hospital level followed by the aggregation of all of the 
hospitals’ averages into one general average. These find-
ings confirm ours about data aggregation and analysis 
choices, but also unveil how data manipulation before 
the statistical analysis occurs in many ways that can 
often be affected by missing data at the individual level.
We recognise some strengths and limitations in this scop-
ing review. On the strengths side, we followed standard 
recommendations for performing and reporting scoping 
reviews.14 It is the first time that the missing data handling in 
ITS studies has been revised and analysed as the main aim of 
a review. The selected studies come from diverse countries 
and journals, and the results of this review are consistent with 
others reported in previous ITS-related reviews,2,3,11–13 which 
is a good indicator of external validity. Among limitations, we 
only considered studies which were published in 2019 but, 
considering outputs from previous ITS-related reviews, it 
seems unlikely that studies from previous years would have 
changed the conclusions. We could have missed some pub-
lications in the search process owing to the use of just one 
database (MEDLINE). However, there are no strong reasons 
to believe that the representativeness of the review has been 
compromised by this factor. We analysed a random sample 
from the population of publications (60/341), meaning that our 
estimates vary about the population value. Thus, although 
some information about missing data handling in ITS studies 
could have been omitted, the overall image of the problem 
studied here is still consistent.
In conclusion, we have demonstrated that reporting and 
handling of missing data rarely occur in ITS studies performed 
for health research. Researchers do not tend to evaluate the 
potential consequences of missing data mechanisms on their 
ITS estimates; their selection of methods for missing data 
handling is thus poorly reflected and informed. The complete 
case analysis is the most commonly applied method, but the 
control for confounding or interactions can be severely affected 
by complete case analyses. Data aggregation is also 
a widespread practice that can affect the validity of the ITS 
estimates when data are missing at random. To overcome these 
issues, we recommend that missing data handling should be 
included ITS guidelines. These guidelines should include 
a recommendation to explore mixed-effects models and/or 
multilevel multiple imputation as more efficient analysis 
alternatives.
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